Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator

被引:86
作者
Jo, MJ
Thomas, KS
Marozkina, N
Amin, TJ
Silva, CM
Parsons, SJ
Gonias, SL
机构
[1] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA
[2] Univ Virginia, Sch Med, Dept Internal Med, Charlottesville, VA 22908 USA
[3] Univ Virginia, Sch Med, Ctr Canc, Charlottesville, VA 22908 USA
[4] Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA
[5] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA
关键词
D O I
10.1074/jbc.M413141200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The urokinase-type plasminogen activator (uPA) receptor ( uPAR) functions in concert with co-receptors, including integrins, FPR-like receptor-1/lipoxin A4 receptor, and the epidermal growth factor receptor ( EGFR), to initiate cell signaling. uPAR co-receptors may be dynamically organized into a multiprotein signaling receptor complex. In Chinese hamster ovary-K1 (CHO-K1) cells, uPA-binding to uPAR activates ERK/ MAP kinase, even though these cells do not express the EGFR; however, when CHO-K1 cells are transfected to express the EGFR, ERK activation becomes EGFR-dependent. In this study, we demonstrate that ERK activation in response to uPA follows equivalent biphasic kinetics in EGFR-expressing and -deficient CHO-K1 cells. In both cell types, the response is pertussis toxin-sensitive; however, uPA promotes cell proliferation exclusively in the EGFR-expressing cells. uPA-induced mitogenic activity requires activation of both STAT5b and ERK. STAT5b was tyrosine-phosphorylated, in response to uPA, only in EGFR-expressing cells. uPA-induced cell proliferation was blocked by dominant-negative MEK1, dominant-negative STAT5b, and by expression of an EGFR that is mutated at Tyr-845, which is essential for STAT5b activation. In two cell culture models of uPA-stimulated breast cancer growth, MDA-MB 468 cells treated with uPA and MCF-7 cells treated with uPA-plasminogen activator inhibitor-1 complex, proliferation was completely inhibited when EGFR expression or activity was blocked. We conclude that expression and assembly of uPAR co-receptors in a specific cell type determines the response to uPA. The EGFR selectively cooperates with uPAR to mediate mitogenesis.
引用
收藏
页码:17449 / 17457
页数:9
相关论文
共 55 条
[1]   Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo [J].
Aguirre-Ghiso, JA ;
Liu, D ;
Mignatti, A ;
Kovalski, K ;
Ossowski, L .
MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (04) :863-879
[2]  
Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684
[3]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[4]  
2-Z
[5]   Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization [J].
Bajou, K ;
Noël, A ;
Gerard, RD ;
Masson, V ;
Brunner, N ;
Holst-Hansen, C ;
Skobe, M ;
Fusenig, NE ;
Carmeliet, P ;
Collen, D ;
Foidart, JM .
NATURE MEDICINE, 1998, 4 (08) :923-928
[6]   Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells [J].
Balmanno, K ;
Cook, SJ .
ONCOGENE, 1999, 18 (20) :3085-3097
[7]   c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function [J].
Biscardi, JS ;
Maa, MC ;
Tice, DA ;
Cox, ME ;
Leu, TH ;
Parsons, SJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (12) :8335-8343
[8]   ESTIMATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR IN 177 BREAST CANCERS - CORRELATION WITH PROGNOSTIC FACTORS [J].
BOLLA, M ;
CHEDIN, M ;
SOUVIGNET, C ;
MARRON, J ;
ARNOULD, C ;
CHAMBAZ, E .
BREAST CANCER RESEARCH AND TREATMENT, 1990, 16 (02) :97-102
[9]   DIFFERENT TRANSFORMING GROWTH FACTOR-ALPHA SPECIES ARE DERIVED FROM A GLYCOSYLATED AND PALMITOYLATED TRANSMEMBRANE PRECURSOR [J].
BRINGMAN, TS ;
LINDQUIST, PB ;
DERYNCK, R .
CELL, 1987, 48 (03) :429-440
[10]  
CARMICHAEL J, 1987, CANCER RES, V47, P943